Rifaximin Modulates the Gut Microbiota to Prevent Hepatic Encephalopathy in Liver Cirrhosis Without Impacting the Resistome

Xiao Yu1,2†, Ye Jin1†, Wangxiao Zhou1, Tingting Xiao1, Zhongwen Wu1, Junwei Su1, Hainv Gao2, Ping Shen1, Beiven Zheng1, Qixia Luo1, Lanjuan Li1 and Yonghong Xiao1*

1 State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China, 2 Department of Respiratory and Critical Care Medicine, First Hospital of Shanxi Medical University, Taiyuan, China, 3 Department of Infectious Disease, ShuLan (Hangzhou) Hospital Affiliated to Zhejiang Shuren University Shulan International Medical College, Hangzhou, China

The gut microbiota has an important role in the pathogenesis of hepatic encephalopathy (HE). Rifaximin, an intestinal non-absorbable antibacterial agent, is effective in the treatment of HE. However, whether long-term prophylactic use induces antibacterial resistance and its mechanism for treating HE remains unclear. This prospective study assessed the impact of 12 weeks rifaximin administration on the gut microbiota and resistome in cirrhotic patients. Fecal sampling was conducted 1 day before the first rifaximin administration and at Weeks 1, 2, 4, 6, 8, 10, 12 of the study. Thirty cirrhotic patients who were in remission from recurrent HE was enrolled to receive rifaximin (400mg TID for 12 weeks). Rifaximin improved hyperammonemia and cognitive function in the 21 patients who completed rifaximin treatment. The dynamic observations showed the gut microbiota diversity, composition and the number of resistance genes, plasmids, insertion sequences did not change significantly during the period (P>0.05). Metabolic pathways such as aromatic amino acids, tryptophan synthesis, urea cycle, and LPS synthesis reduced. No new antimicrobial resistance genes was emergended. However, the number of aminoglycosides, rifamycin and phenolic resistance genes increased, whereas tetracycline, fosfomycin and cephamycin decreased (P<0.05). Changes in the abundance of E. coli, K. pneumoniae, and B. longum strains correlated with changes of resistance genes. Prophylactic use of rifaximin for 12 weeks improved hyperammonemia and cognitive function in the 21 patients who completed rifaximin treatment. The dynamic observations showed the gut microbiota diversity, composition and the number of resistance genes, plasmids, insertion sequences did not change significantly during the period (P>0.05). Metabolic pathways such as aromatic amino acids, tryptophan synthesis, urea cycle, and LPS synthesis reduced. No new antimicrobial resistance genes was emergened. However, the number of aminoglycosides, rifamycin and phenolic resistance genes increased, whereas tetracycline, fosfomycin and cephamycin decreased (P<0.05). Changes in the abundance of E. coli, K. pneumoniae, and B. longum strains correlated with changes of resistance genes. Prophylactic use of rifaximin for 12 weeks improved hyperammonemia and neurophysiological function, maintained gut microbiota diversity, composition and did not change the overall resistome. Rifaximin altered expression of HE-related metabolic pathways. All of these effects could play a key role in preventing HE.

Clinical Trial Registration: ChiCTR1900022234 (registered at the Chinese Clinical Trial Registry).

Keywords: liver cirrhosis, gut microbiota, metagenomics, resistome, rifaximin
INTRODUCTION

Chronic liver disease is common, and hepatic encephalopathy (HE) is a common serious complication with a high mortality rate in patients with end-stage cirrhosis. The main drugs currently used for prevention and treatment of HE are L-ornithine-L-aspartate, lactulose, lactitol, and rifaximin. Rifaximin (as the only available crystalline form rifaximin in clinical, rifaximin refers to rifaximin-α in this article) is a rifamycin derivative with low absorption that may exert pharmacological actions through its effect on the gut microbiota (Kogawa and Salgado, 2018). In 2010, the US FDA approved rifaximin for prevention and treatment of HE; indeed, EASL-AASLD guidelines (2014 version) for the treatment of HE recommends this drug as an effective add-on treatment for patients with overt HE (i.e., those who develop the disease while taking lactulose) and for preventing recurrence of HE. In addition, the Consensus Opinion on the Diagnosis and Treatment of HE in China (2013) recommends rifaximin as a widely available drug for preventing the recurrence of HE (FDA Approves New Use of Xifaxan for Patients With Liver Disease, 2010); Chinese Society of Hepatology Chinese Medical Association, 2013; American Association for the Study of Liver Diseases and European Association for the Study of the Liver, 2014). The mechanism by which rifaximin prevents and treats of HE is still not fully understood.

The human gut is rich in microorganisms, which play an important role in maintaining homeostasis in the body (Ley et al., 2006; Brenchley Jason and Douek Daniel, 2012; Acharya et al., 2017). Antibiotics such as vancomycin, imipenem, and ciprofloxacin have been reported to extremely reduce the diversity and increase antibiotic resistance in the gut microbiota (Morgen et al., 2015; Gibson Molly et al., 2015; Choo et al., 2017). Rifaximin is an antimicrobial drug that is not absorbed from the gut; therefore, it accumulates at high concentrations in the gut after oral administration. The effect of rifaximin on the gut microbiota and resistome after long-term prophylactic and therapeutic use for HE is unclear. Studies based on 16s rRNA gene amplicon sequencing report that rifaximin does not affect gut microbiome diversity, and that it has very little effect on bacterial abundance in the microbiome (Bajaj et al., 2013). Therefore, it is hypothesized that changes in bacterial metabolic function, rather than changes in bacterial populations, underlie the primary mode of action of rifaximin for treating HE. In addition, serum metabolomics show an increase in serum linoleic, linolenic, and arachidonic unsaturated fatty acid content, and a decrease in lipopolysaccharide content, after rifaximin treatment, suggesting that rifaximin changes metabolic function in the gut microbiota (Bajaj et al., 2013; Kaji et al., 2017). However, 16s RNA amplicon sequencing has limited resolution, and so gut microbiota are generally annotated to the genus level (rather than the species level); by contrast, the application of metagenome sequencing allows independent analysis of changes in gut microbiota populations and functions (Lepage et al., 2013; Bajaj and Khoruts, 2020).

Antimicrobial resistance has become a serious public health crisis; the emergence of multi-drug resistance and pan-drug resistance bacterial is common in clinical practice, resulting in bacterial infections that are often untreatable and pose a serious threat to life. Indeed, antimicrobial resistance has attracted great attention from the World Health Organization and national governments (Metcalfe et al., 2016; Xiao, 2018; Zhou et al., 2018; Wu et al., 2019). The gut contains a wide variety of bacteria and can be considered an antimicrobial resistance gene pool. The effects of various antimicrobial drugs on gut bacterial resistance have been reported widely, with the use of meropenem, ticarcillin/clavulanate, cefotaxime, gentamicin, and vancomycin increasing the number of their corresponding resistance genes in the gut microbiota (Gasparrini et al., 2016). The effect of long-term prophylactic use of rifaximin on gut microbiota resistance in patients with cirrhosis also deserves an in-depth study to avoid worsening of resistance.

The purpose of this study was to investigate dynamic changes in the gut microbiota of cirrhotic patients during 12 weeks rifaximin administration, and to study possible therapeutic mechanisms of rifaximin-α, as well as to understand the effect of rifaximin on gut antimicrobial resistance genes and to make recommendations for the rational clinical use of rifaximin in cirrhotic patients.

PATIENTS AND METHODS

Study Design and Patient Enrollment

This prospective study was conducted in accordance with the Declaration of Helsinki and approved by the ethics committee of the First Affiliated Hospital, College of Medicine, Zhejiang University, China (No:RN.2017.665). Eligible cirrhotic patients were enrolled to receive rifaximin (400mg TID for 12 weeks). All patients were treated routinely according to the guidelines for the diagnosis and treatment of cirrhosis (Chinese Society of Hepatology Chinese Medical Association, 2013). Additional protocols and inclusion/exclusion criteria are described in the supplement materials.

Specimen Collection, Genome Extraction, and Metagenomics Sequencing

Stool specimens were collected one day before drug administration and at week 1, 2, 4, 6, 8, 10 and 12 weeks of the study, ensuring that each specimen weighed more than 1 g. The genomes of bacteria present in stool samples were extracted using a commercially available kit (Qiagen), according to the manufacturer's instructions. The DNA concentration of the extracted genome was measured and sequenced on an Illumina Novaseq 6000 instrument, with 10G of sequencing data per sample.

Taxonomic, Functional Profiling and Correlation Analysis of Gut Microbiota and Resistance Genes

Taxonomic profiling of the stool samples was performed using MetaPhlAn2 v2.5.0 with default settings. Abundance of metabolic pathways was performed with HUMANAN2v0.9.4. The antimicrobial resistance genes analysis was performed...
using the bwt function in the rgi software package. The correlation between gut microbiota and resistance genes was based on co-occurrence analysis. The “igraph” and “Hmisc” packages in R language were used to calculate the correlation matrix between resistant genes and strains by WGCNA (weighted gene co-expression network analysis). Correlation matrix R values and correlation matrix p values between resistance genes and strains were calculated, and p values were adjusted using the Benjamini-Hochberg method correction. The above matrix was graphically displayed using Gephi software.

**Statistical Methods**
Measurement data were expressed as the mean ± standard deviation (x ± s). Data that were normally distributed were tested using either a Student’s t-test (including independent and paired samples), Fisher’s exact test, or an ANOVA test. A non-parametric Wilcoxon test was used for non-normally distributed data. A chi-square test was used for the count data. The ANOSIM (analysis of similarities) non-parametric test was used to analyze differences in principal coordinate analysis. Data were processed using R statistical software. A P-value < 0.05 was considered statistically significant.

**Data Availability Statement**
Metagenomic sequencing data for all samples have been deposited in the NCBI Sequence Read Archive database under accession numbers PRJNA689208 (https://www.ncbi.nlm.nih.gov/bioproject/PRJNA689208).

**RESULTS**

**Characteristics of the Study Population**
Thirty cirrhotic patients were enrolled in the study from March, 2018 to May, 2019, all of whom belonged to CTP(Child-Turcotte-Pugh) class A; 21 patients completed the study protocol (Figure 1). Stool samples from 20 patients underwent metagenomic analysis (one patient had insufficient DNA in their stool sample for metagenomic sequencing) (Figure 1).

Basic patient information and patient medication use during the study period were described in the supplemental material (Supplementary Table 1). No significant changes in blood pressure, heart rate, alpha-fetoprotein levels, hepatitis B markers, CA-199 levels, CA-125 levels, liver and kidney function, or routine blood and urine test results were observed during the study (Supplementary Table 2). Blood ammonia concentrations fell gradually in patients without HE during the study period (from 54.1 ± 14.7 μmol/L to 25.6 ± 9.7 μmol/L; P < 0.05). There was a statistically significant improvement in the time taken by patients to complete NCT-A(number connection test) scores (from 121.4 ± 20.3 s to 112.3 ± 18.4; P < 0.05) and DST(digit symbol test) scores (8.3 ± 2.1 to 10 ± 3.1; P < 0.05) after rifaximin administration (Table 1).

Four patients experienced transient diarrhea during the dosing period, which improved without treatment. Nine patients underwent transjugular intrahepatic portosystemic shunt (TIPS), of which four developed HE during the drug administration regimen. One patient in the non-TIPS group (comprising 12 patients) developed HE during drug administration.

**Gut Microbiota Composition in Patients With Cirrhosis and the Impact of Rifaximin**
The gut microbiota of the patients included in this study was comparable to the results of previous studies (Qin et al., 2014). As 11 phyla(184 genera, 506 species) were identified in the gut microbiota of the patients in this study. The dominant phylum (genera, species) present in the gut microbiota differed in each patient (Supplementary Figure 1A, and Figures 2, 3). There was a decreasing trend in the abundance of Firmicutes and an increase in the abundance of Proteobacteria during rifaximin
administration (Supplementary Figure 1B). Rifaximin caused a decreased trend in the abundance of *Veillonella*, *Haemophilus*, *Streptococcus*, *Parabacteroides*, *Roseburia*, *Alistipes*, *Ruminococcus*, and *Lactobacillus*. There was an increasing trend in the abundance of *Blautia*, *Fusobacterium*, *Prevotella*, and *Klebsiella* caused by rifaximin treatment at the genus level (Supplementary Figure 2B). At the species level, there was a trend toward an increase in abundance of *Escherichia coli*, *unclassified Escherichia*, *Klebsiella pneumoniae*, *Faecalibacterium prausnitzii*, *Bacteroides thetaiotaomicron*, and *Bacteroides uniformis*, and a trend toward a decrease in the abundance of *Bifidobacterium breve*, *Roseburia intestinalis*,

![FIGURE 2](image1.png)

**FIGURE 2** | Changes in gut microbiota (at a species level) in patients over time. Horizontal coordinates denote sampling time points; a–h represent Day 1, Week 1, Week 2, Week 4, Week 6, Week 8, Week 10, and Week 12, respectively. Vertical coordinates denote the relative abundance of the species (%).

![FIGURE 3](image2.png)

**FIGURE 3** | Comparison of, and changes in, the gut microbiota (at the species level) in patients with and without HE. (A) Composition of gut microbiota in patients with and without HE. (B) Changes in the abundance of 119 species of bacteria in patients with (left side) and without (right side) HE after rifaximin administration. Horizontal coordinates denote sampling time points; a–h represent Day 1, Week 1, Week 2, Week 4, Week 6, Week 8, Week 10, and Week 12, respectively.

| Group          | Content            | Start day | Week 1 | Week 4 | Week 8 | Week 10 | Week 12 |
|----------------|--------------------|-----------|--------|--------|--------|---------|---------|
| No HE (n=16)   | Ammonia (μmol/L)   | 54.1±14.7 | 42.1±8.3* | 47.5±5.6* | 35.3±8.6* | 31.2±7.3* | 25.6±9.7* |
|                | NCT-A (s)          | 121.4±20.3 | 118.4±10.5* | 111.4±17.3* | 105.4±20.3* | 108.1±30.3* | 112.3±18.4* |
|                | DST                | 8.3±2.1   | 9.2±1.4* | 9.1±3.1* | 9.8±2.4* | 9.3±2.1* | 10.1±3.1* |
| HE(n=5)        | Ammonia (μmol/L)   | 52.6±10.3 | 47.6±9.8* | 52.8±8.9 | 68.2±16.7* | 69±19.7* | 44±10.1* |
|                | NCT-A (s)          | 123±6.7   | 128.6±10.2 | 134±15.1* | 152.2±24.7* | 159.8±19.4* | 133.8±15.7* |
|                | DST                | 8.2±1.3   | 8.2±3.1   | 7.8±4.7 | 6.8±6.9* | 6±8.7* | 6.8±2.8* |

*Statistically significant difference compared with the starting day (p<0.05).
Ruminococcus bromii, Megamonas funiformis, and Collinsella aerofaciens (p<0.05) during the dosing period (Figure 2). The abundance of the remaining species fluctuated during the treatment period.

Comparison of Gut Microbiota in Patients With and Without HE
The Firmicutes, Candidatus Saccharibacteria, and the Verrucomicrobia phyla were significantly lower in patients with HE (P<0.05) than in patients without HE, whereas Bacteroidetes and Proteobacteria were significantly higher in patients with HE (P<0.05) than in patients without HE (Supplementary Figure 4). The diversity of the gut microbiota was significantly lower in HE patients than in non-HE patients (P <0.05). There were 119 species differences between the two groups of patients (P<0.05), including 43 species that were present in higher abundance in HE patients and 76 strains that were higher in patients who did not develop HE (Supplementary Table 3). These 43 species mainly included K. pneumoniae, K. oxytoca, unclassified Klebsiella, E. faecalis, E. cloacae, E. faecalis, C. freundii, R. aquatilis, and S. mitis oralis (Figure 3B). Of the 43 species that were high in HE patients, 23 increased further during the study period in HE patients, but decreased in patients without HE. The 76 species that were present in high abundance in non-HE patients included L. vaginalis, F. prausnitzii, R. obeum, A. muciniphila, B. pseudocatenulatum, and B. breve, and the abundance of these species remained stable during the dosing period (Figure 3B).

Effect of Rifaximin on the Diversity of the Gut Microbiota
The diversity indices of the gut microbiota were calculated at the species level. Rifaximin treatment reduced both the number of species and the chaol index in the gut microbiota only at Week 4; the number of observed species was not changed at other time points. The Shannon and Simpson indices did not change significantly during drug administration (maintained at 2.3 ± 1.5 and 0.8 ± 0.07, respectively; Supplementary Figure 5A). Based on principal coordinate analysis, the composition of the patient gut microbiota did not change significantly [as measured by the ANOSIM test, which did not show significant differences; R=-0.029, P>0.995 (Supplementary Figure 5B)]. The diversity of the gut microbiota was significantly lower in patients who experienced episodes of HE than in those who did not (P<0.05) (Figure 4A). The diversity of the gut microbiota (number of observed species, chaol index, Shannon index, and Simpson index) remained stable during rifaximin administration in patients who did not develop HE (P>0.05), whereas there was a non-significant trend toward decreased diversity (mean 76.6 ± 5.1 to 53.3 ± 10.1) in patients who

FIGURE 4 | Comparison of microbiota diversity (at the species level) in patients with and without HE. Each point in the figure represents a patient: individual colors represent an individual patient. (A) Comparison of the overall gut microbiota diversity in patients with and without HE. The diversity of the microbiota was significantly lower in patients with HE than in patients without HE. The numbers in the figure show the statistical P-values between the two groups. (B) Changes in gut microbiota diversity between patients with and without HE during drug administration. Horizontal coordinates denote sampling time points, with a–h representing Day 1, Week 1, Week 2, Week 4, Week 6, Week 8, Week 10, and Week 12, respectively. Vertical coordinates represent the four indicators of bacterial diversity.
developed HE (Figure 4B). In addition, there was a significant decrease in the diversity of the microbiota at the time of HE occurrence (the Shannon index decreased by 0.2 to 0.8), followed by a gradual recovery (Supplementary Figure 6).

Altered Metabolic Pathways in the Gut Microbiome Associated With HE
Among the 535 metabolic pathways identified, there were 206 differences (P<0.05) between patients who suffered HE and those who did not, of which 67 pathways were decreased in patients with HE and 139 pathways were increased (Supplementary Table 4 and Figure 5A). These differential metabolic pathways were mainly involved in synthesis of phosphopептидic acid, peptidoglycans, amino acids, and fatty acids; in degradation of alcohols; in degradation of rockulose and rhamnose; and in synthesis and degradation of coenzymes. Thirty-nine metabolic pathways related to HE were selected for analysis; the results showed that 17 pathways related to HE patients increased during rifaximin administration. These pathways could be classified as five main types: synthesis of branched-chain amino acids (type I, n=4); pathways related to ammonia metabolism (type II, n=9); synthesis of aromatic amino acids (type III, n =2); increased synthesis of tryptophan (type IV, n=1); and synthesis of LPS (type V, n=1) (Figure 5B). These selected pathways remained stable in non-HE patients.

Genomic Variation of Gut Strains Under the Influence of Rifaximin
A total of 35 species with genome sequencing coverage >20% and sequencing depth >15X showed genomic variation. COG annotation of SNV-mutated genes revealed that about 10.1% of SNV genes were related to gene transcription and 8.3% were related to bacterial replication and repair functions, whereas 6.1% of mutations occurred in genes related to glycan transport, 6.0% occurred in genes related to lipid transport, and 4.1% occurred in genes related to energy metabolism (Supplementary Figure 7). These mutations may lead to changes in expression of metabolic pathways. After administration of rifaximin, the species found to have substitutions based on SNV after WSS calculations included E. coli, B. longum, C. aerofaciens, V. parvula, P. prausnitzii, L. salivarius, L. fermentum, and B. uniformis. Some of these strains will be stable in patients after substitution, including B. capillosus, A. shahii, and R. gnarus, whereas some will be replaced by the original strains after substitution, including L. fermentum, C. aerofaciens, and V. parvula (Supplementary Figure 8). Based on the grid growth rate index calculated by SNV, E. coli, B. longum, C. aerofaciens, F. prausnitzii, R. gnarus, A. shahii, and B. uniformis showed increased growth rates after rifaximin treatment. The growth rate of V. parvula, C. bolteae, C. nexile, L. fermentum, and L. salivarius was reduced after rifaximin treatment.

Changes in the Gut Resistome After Rifaximin Treatment
A total of 1845 drug resistance genes were identified in the gut microbiome of patients; the number of drug resistance genes carried by each patient ranged from 23 to 343. The number and abundance of drug-resistant genes in the gut microbiome of patients remained stable during the drug administration period, and there was no statistical difference compared with the pre-drug period (Figure 6). The number of resistance genes carried by the gut microbiota of patients in the TIPS group (22.3 ± 5.7) was higher than that in the non-TIPS group (18.1 ± 4.5) (P<0.05), but there was no significant difference in the abundance of resistance genes between the two groups (P>0.05) (Figures 7A, B, D, E). The number and abundance of resistant genes did not change in either
the TIPS or non-TIPS group after rifaximin treatment was initiated, and remained stable through the study period (Figures 7C, F). The composition of gut resistance genes was similar in the TIPS and non-TIPS groups, and it remained stable during rifaximin administration (Figure 7G).

Changes in the Types of Antimicrobial Resistance Genes in the Gut of Cirrhosis Patients

Resistance genes are characterized according to the antimicrobial agent first found to mediate resistance. The stool samples of the patients in this study contained 24 types of antimicrobial resistance genes. Rifamycin-related resistance genes accounted for about 3.6%. Four types of change in resistance genes were identified during the dosing period. This first is a gradual increase, which was observed for genes conferring resistance to aminoglycosides, phenicol antibiotics, and rifamycin (P<0.05). The second change is a decrease and then an increase, which was observed for genes conferring resistance to lincosamides and glycopeptides. The third change is an increase and then a decrease, as seen for genes conferring resistance to cephalosporins and mupirocin. The fourth
change is a gradual decrease, as observed for genes conferring resistance to tetracyclines and cephalosporins. (P<0.05) (Supplementary Figure 9). Moreover, TIPS patients carried significantly more resistance genes than non-TIPS patients, and the increase in the number of resistance genes, such as genes conferring resistance to aminoglycosides, rifamycins, and phenolics, occurred in the gut microbiota of TIPS patients during the study (P<0.05), while the numbers of these three types of resistance gene remained stable in non-TIPS patients (Supplementary Figure 10).

Clinically important carbapenemase genes such as blaNDM, blaKPC, blaVIM, and blaIMP, as well as the vanA and vanB vancomycin resistance genes, were not detected in cirrhotic patients in this study; however, the vanC, vanD, vanRG, and vanRC resistance genes were detected.

Numbers and Types of Mobile Elements in the Gut Microbiome of Patients With Cirrhosis

A total of 95 plasmid types were carried in the gut microbiota of patients with cirrhosis, with the most abundant being IncFIB plasmids (accounting for 11.37% of all plasmids). Each patient carried 11–20 plasmids, with an average of 10.1 ± 3.9 plasmid types per patient, and carriage remained stable throughout the study period (Supplementary Figure 11). A total of 781 diverse IS were carried in the gut microbiota of cirrhotic patients, with no clear dominant type. Each patient carried 18–89 IS, with an average of approximately 1219.7 ± 301.4 IS sequences, and carriage remained stable and similar to the trend in plasmid carriage observed during rifaximin administration (Supplementary Figure 12).

Correlation Between Gut Microbiota and Resistance Genes in Patients With Liver Cirrhosis

To the analysis of the co-occurrence relationship between gut bacterial abundance and drug-resistant gene abundance, the threshold was set to be more than 0.5 and the p-value was less than 0.05. At the species level, nine species were highly associated with drug-resistant genes (Figure 8), and included E. coli, unclassified Escherichia, K. pneumoniae, and E. mori. Aminoglycosides, cephalosporins, quinolones, phosphomycins, macrolides, and phenol drug resistance genes were associated mainly with E. coli. Carbapenems, aminoglycosides, aminocoumarins, chloramphenicol, and monocyclic lactam drug resistance genes were associated mainly with K. pneumoniae, and rifamycin resistance genes were associated mainly with B. longum. The lincosamides, glycopeptides, tetracyclines, and cephalosporins were not associated significantly with any strains. Mupirocins were associated mainly with Oligella ureolytica. In addition, we found a strong correlation between resistance genes, further suggesting that these resistance genes may be located in the same strain. Thus, changes in the gut resistome during rifaximin-a use were associated mainly with changes in strain abundance, leading to changes in the number of resistance genes.

DISCUSSION

In this study, 12 weeks administration of rifaximin reduced blood ammonemia and improved neurophysiological functions in patients with cirrhosis, which is in agreement with a previous report (Bass Nathan et al., 2010). HE (West-Haven >2) occurred in five patients during the study, and except for one patient in whom excessive meat consumption was an obvious trigger for the onset of HE, all patients were post-TIPS patients with no significant changes to their usual diet. An increased incidence (30–40%) of HE has been confirmed in post-TIPS patients (Riggio et al., 2005). In addition, this study found that long-term administration of rifaximin was well tolerated, with a low incidence of general adverse events.

Stable gut microbiota diversity is of great value in maintaining liver function. Sung et al. found that the diversity of the gut microbiota decreased during onset of HE, and recovered partially during the recovery period, suggesting that changes in diversity of the gut microbiota are involved in the pathogenesis of HE (Sung et al., 2019). In this study, we also found that the diversity of the gut microbiota decreased significantly in patients who developed HE compared with those who did not, and that the decrease was most pronounced during the onset of HE. Therefore, maintaining gut microbiota diversity is important for preventing hepatic encephalopathy. Our results show that rifaximin has little effect on the diversity of the gut microbiota. In a previous cohort study, Bajaj et al. used 16s amplicon
sequencing to evaluate the effect of rifaximin on the gut microbiome of patients with cirrhosis and found that rifaximin had little effect on the diversity of the gut microbiota (Kaji et al., 2017). By contrast, other antimicrobial drugs such as cefprozil, vancomycin, and ciprofloxacin decreased the number of bacterial species in the gut microbiota significantly (Raymond et al., 2016; Reijnders et al., 2016).

In addition to maintaining the diversity of gut strains, long-term administration of rifaximin may also modulate the abundance of the gut microbiota (Acharya et al., 2017). Rifaximin slightly reduced the abundance of Firmicutes, and increased the abundance of Bacteroides, in cirrhosis patients. Patients with HE had significantly higher levels of potentially harmful strains such as K. pneumoniae, K. oxytoca, E. faecalis, and C. freundii in the intestine than patients without HE, while potentially beneficial strains such as L. vaginalis, F. prausnitzii, A. muciniphila, and B. pseudocatenulatum, and B. breve were significantly lower in patients with HE. These findings are in agreement with the results of previous studies (Qin et al., 2014; Llorente and Schnabl, 2015). The presence of the Enterobacteriaceae species is related to the initiation of inflammation in the gut, to the development of cirrhosis. K. pneumoniae and C. freundii are involved in the development of inflammatory bowel diseases (Henke Matthew et al., 2019), and their lipopolysaccharides can destroy the mucosa of the intestine (Song et al., 2017). We found that the abundance of A. muciniphila was significantly higher in patients without HE, and increased slightly during rifaximin administration. The abundance of A. muciniphila is negatively associated with various diseases such as IBD, obesity, acromegaly, metabolic disorders, autism, insulin resistance epilepsy, and hypertension (Everard et al., 2013; Ogata et al., 2020; Wu et al., 2020; Zhu et al., 2020). During the study period, rifaximin increased the abundance of F. prausnitzii, a strain that produces anti-inflammatory effects that significantly improve gut inflammation and control obesity (Sokol et al., 2008; Miquel et al., 2013). Besides, administration of rifaximin reduced the abundance of bacteria associated with intestinal barrier damage, including Clostridium perfringens (which has an important role in the pathogenesis of inflammatory bowel disease) (Everard et al., 2013) and R. intestinalis (which can destroy the mucosa of the intestine) (Song et al., 2017). At the same time, rifaximin maintained the abundance of probiotics. These results suggest that rifaximin may prevent HE by regulating the abundance of different strains in the gut microbiota, by reducing the abundance of harmful bacteria, and by maintaining the abundance of beneficial bacteria.

Analysis of metabolic pathways in the gut microbiota of cirrhosis patients revealed that differential activation of metabolic pathways between HE patients and non-HE patients mainly involved pathways related to cell wall synthesis and metabolism of molecules such as phosphopeptidic acid, peptidoglycan, LPS, amino acids, and fatty acids. This result indicates that these metabolic pathways may play an important role in the development of HE, although further studies are needed to confirm this. Analysis of changes in HE-related metabolic pathways revealed that those related to synthesis of aromatic amino acids, tryptophan, LPS, and branched-chain amino acids, as well as those related to the urea cycle, increased in HE patients and were either stable or decreased in non-HE patients, suggesting that metabolic changes in the gut microbiota are involved in the pathogenesis of HE. We also found that branched-chain amino acid synthesis increased, suggesting that the gut microbiota compensates for increased branched-chain amino acid synthesis during HE pathogenesis. Analysis of these metabolic enhancements in conjunction with changes in the microbiota revealed that they may be mainly due to increased abundance of Enterobacteriaceae strains in the gut microbiota of cirrhosis patients. This result suggests that Enterobacteriaceae strains have an important role in promoting HE. In addition, branched-chain amino acids, aromatic ammonia, the urea cycle, and LPS-related metabolic pathways remained stable in non-HE patients, suggesting that rifaximin may prevent development of HE in cirrhotic patients by stabilizing these metabolic pathways.

The effect of long-term rifaximin administration on the genome of bacterial strains is not known. In this study, analysis of mutations in the SNV of strains showed that 12 weeks rifaximin use leads to mutations in the genome of specific strains in the gut microbiota, that these mutations lead to changes in corresponding functions, and that these functional changes alter the activity of metabolic pathways. The WSS algorithm predicted that the presence of these mutations was due to strain substitution. The main strains in which substitution occurred were E. coli, B. longum, C. perfringens, and C. pratense. After SNV occurred, the growth rate (predicted by the grid growth rate index) changed from strain to strain. Thus, under the action of rifaximin, subpopulations that were formerly dominant were gradually replaced by other subpopulations of the same species with faster growth rates. Interestingly, these substituted strains still largely maintained the abundance of the original species in the gut microbiota, further suggesting that the gut microbiota is stable, with different species forming a relatively constant proportion of the gut microbiota (D’Argenio and Salvatore, 2015). Due to the limitations of the current analysis algorithm, our results need further validation, and further studies are needed to elaborate the preventive value of the functional alterations caused by the genomic variation of the strain on the pathogenesis of HE.

Several studies show that rifaximin prevents development of HE, but the mechanism by which this occurs is not clear (Bass Nathan et al., 2010; Ito et al., 2019; Coronel-Castillo et al., 2020; Labenz et al., 2020; Lv et al., 2020). Although rifaximin exerts antibacterial effects against a wide range of Gram-positive and Gram-negative bacteria in vitro, our study found that rifaximin administration did not affect the stability of the gut microbiota, and that the antibacterial effect of rifaximin in the intestine was not significant. Previous studies show that rifaximin reduces plasma levels of endotoxin in patients by modulating the permeability of the gut barrier (Bajaj and Khoruts, 2020). In vitro studies performed in human gut epithelial cells indicate that rifaximin decreases apoptosis and increases tight junction protein expression by activating the TLR4/MyD88/NF-κB pathway.
pathway, thereby increasing gut barrier function (Douhara et al., 2015; Esposito et al., 2016). The pharmacological effects of rifaximin on bacterial strains may also involve alterations in bacterial function and virulence, rather than reductions in bacterial populations (Jiang et al., 2010). Rifaximin treatment prevents HE by inhibiting bile acid production and reducing endotoxemia without altering microbiota composition (Ridlon et al., 2013). Our study suggests that rifaximin modulates gut microbiota function; the drug stabilizes gut microbiota composition and species abundance, and regulates expression of bacterial metabolic pathways through genomic variation. Through these actions, rifaximin exerts therapeutic and preventive effects on HE.

Whether long-term oral non-absorption of antimicrobial drugs leads to increased resistance is another important concern addressed by this study. We found that the greatest number of resistance genes in the gut tract of cirrhosis patients was related to penicillins, followed by tetracyclines, macrolides, and quinolones. By contrast, resistance genes in the gut microbiota of healthy people are mostly related to tetracycline antimicrobial drugs. The reason for the differences between cirrhosis patients and healthy individuals may be related to frequent hospitalization and higher frequency of antimicrobial drug use in cirrhosis patients, resulting in higher levels of resistance genes (Chaulk et al., 2014; Fernandez et al., 2016). During the 12 weeks of rifaximin administration, there was no significant increase in the total number or abundance of gut resistance genes in patients. Changes in the number of resistance genes were mostly associated with Enterobacteriaceae such as E. coli and K. pneumoniae, and were consistent with the process of strain changes during rifaximin administration. This finding suggests that changes in strain abundance are responsible for resistance gene changes.

A recently published study showed that patients prescribed rifaximin developed rifampin-resistant staphylococcal isolates after as little as 1-7 weeks of rifaximin treatment (Chang et al., 2017). In this study, the rifampicin resistance genes [rifampin ADP-riboyltransferase (arr), mutations in rifamycin-resistant beta-subunit of RNA polymerase (rpoB)], were found located mainly on B. longum or E. coli strains. while Staphylococcus mainly carry the aph(2’), aac(6’),poxtA, erm, fexA, tetM genes which mediate resistance to aminoglycoside, macrolide antibiotics, tetracycline respectively. However, since the previous study did not analyze the resistance mechanism, it is difficult to speculate the reason for the difference and anyway the difference between the experimental results and the sequencing results indicates that more research is needed to explore the effect of rifaximin on antibiotic resistance. In addition, no clinically important resistance genes were observed during 12 weeks use of rifaximin, and there was no significant increase in plasmids and insertion sequences related to carriage and transmission of resistance genes.

This study did not control for factors such as patient diet, lifestyle habits, and drug treatments other than antimicrobial drugs. Furthermore, differences between individuals’ life history and genetics can alter the gut microbiome. Together, these factors could influence the effect of rifaximin on the gut microbiome and drug resistance genes (Dethlefsen and Relman David, 2011). Though the number of patients included in this study was small, and many of the results were trends that did meet statistical significance, the multiple sampling and dynamic changes over time partly verify the results. Certainly, further more studies, including studies that account for patient factors, are needed to support and extend the conclusions of this study.

In conclusion, 12 weeks administration of rifaximin to patients with cirrhosis is well tolerated, reduces blood ammonia, and improves neurophysiological functions. Rifaximin does not appear to function as an antimicrobial agent in the prevention and treatment of hepatic encephalopathy, but rather as a gut microbiota regulator for the prevention of hepatic encephalopathy. Administration of rifaximin may maintain and functionally regulate the overall composition and diversity of the gut microbiota, which may reduce the abundance of harmful bacteria (e.g., Klebsiella, Streptococcus, and Clostridium), and increase the abundance of probiotic bacteria (e.g., Bifidobacterium and Bacteroides), in patients with liver cirrhosis. These changes in bacterial abundance in the gut microbiota may prevent HE by reducing the activity of metabolic pathways associated with HE attacks. 12 weeks Prophylactic administration of rifaximin in patients with cirrhosis does not alter the type and abundance of drug-resistant genes in the gut microbiota, and the number and type of drug-resistant-associated mobile elements in the gut microbiota remain stable during rifaximin administration. The induction of resistance to antimicrobial agents may not be a concern when prophylactic use this drug.

DATA AVAILABILITY STATEMENT

The datasets presented in this study can be found in online repositories. The names of the repository/repositories and accession number(s) can be found in the article/Supplementary Material.

ETHICS STATEMENT

The studies involving human participants were reviewed and approved by the ethics committee of the First Affiliated Hospital, College of Medicine, Zhejiang University. The patients/participants provided their written informed consent to participate in this study.

AUTHOR CONTRIBUTIONS

XY, YJ, and WZ were involved in microbiome analysis, bioinformatics interpretation and research conduct. XY, ZW, JS, PS, and HG were involved in sample collection and providing clinical support. XY, BZ, QL, and TX were involved in data analysis and manuscript drafting. LL and YX conceived and
designed the study. All authors contributed to the article and approved the submitted version.

**FUNDING**

This work was supported by The Key National Research and Development Program of China (grant number 2017YFC1200203), the National Natural Science Foundation of China (grant number 81971984), the Mega-projects of Science Research of China (grant number 2018ZX10733402-004).

**REFERENCES**

Acharya, C., Sahingur, S. E., and Bajaj, J. S. (2017). Microbiota, Cirrhosis, and the Emerging Oral-Gut-Liver Axis. *JCI Insight* 2 (19), e94416. doi: 10.1172/jci.insight.94416

American Association for the Study of Liver Diseases and European Association for the Study of the Liver (2014). Hepatic Encephalopathy in Chronic Liver Disease: 2014 Practice Guideline by the European Association for the Study of the Liver and the American Association for the Study of Liver Diseases. *J. Hepatol.* 61, 642–659. doi: 10.1016/j.jhep.2014.05.042

Bobo, EG. (2010). FDA Approves New Use of Xifaxan for Patients With Liver Disease. Available at: https://www.drugs.com/newdrugs/fda-approves-new-xifaxan-patients-liver-2078.html.

Bajaj, J. S., Heuman, D. M., Sanyal, A. J., Hylemon, P. B., Sterling, R. K., Stravitz, R. T., et al. (2013). Modulation of the Metabotome by Rifaximin in Patients With Cirrhosis and Minimal Hepatic Encephalopathy. *PloS One* 8, e60042. doi: 10.1371/journal.pone.0060042

Bajaj, J. S., and Khuroo, A. (2020). Microbiota Changes and Intestinal Microbiota Transplantation in Liver Diseases and Cirrhosis. *J. Hepatol.* 72, 1003–1027. doi: 10.1016/j.jhep.2020.01.017

Bass Nathan, M., Mullenn Kevin, D., Sanyal, A., Poordad, F., Neff, G., Leevy, C. B., et al. (2010). Rifaximin Treatment in Hepatic Encephalopathy. *N. Engl. J. Med.* 362, 1071–1081. doi: 10.1056/NEJMoa0907893

Brenchley Jason, M., and Douek Daniel, C. (2012). Microbial Translocation Across the GI Tract. *Annu. Rev. Immunol.* 30, 149–173. doi: 10.1146/annurev-immunol-020711-070051

Chang, J. Y., Kim, S. E., Kim, T. H., Woo, S. Y., Ryu, M. S., Yoo, J. H., et al. (2017). Emergence of Rifaximin-Resistant Staphylococci After Rifaximin Administration in Cirrhotic Patients. *PloS One* 12 (10), e0186120. doi: 10.1371/journal.pone.0186120

Chauk, J., Carbonneau, M., Qamar, H., Keough, A., Chang, H. J., Ma, M., et al. (2014). Third-Generation Cephalosporin-Resistant Spontaneous Bacterial Peritonitis: A Single-Centre Experience and Summary of Existing Studies. *Can. J. Gastroenterol. Hepatol.* 28, 83–88. doi: 10.1155/2014/429336

Chinese Society of Hepatology Chinese Medical Association. (2013). Guidelines for the Diagnosis and Management of Hepatic Encephalopathy in Cirrhosis [Article in Chinese]. *Zhonghua Gan Zang Bing Za Zhi* 26, 721–736. doi: 10.3760/cma.j.issn.1007-3418.2013.09.001

Choo, J. M., Kanno, T., Zain, N. M., Leong, L. E., Abell, G. C., Keeble, J. E., et al. (2017). Divergent Relationships Between Fecal Microbiota and Metabolome Following Distinct Antibiotic-Induced Disruptions. *mSphere* 2, e00005–e00017. doi: 10.1128/mSphere.00005-17

Coronel-Castillo, C. E., Contras-Carmona, J., Frati-Munari, A. C., Uribe, M., and Méndez-Sánchez, N. (2020). Efficacy of Rifaximin in the Different Clinical Scenarios of Hepatic Encephalopathy. *Rev. Gastroenterol Mex* 85, 56–68. doi: 10.1160/rgmxen.2019.09.003

D’Argenio, V., and Salvatore, F. (2015). The Role of the Gut Microbiome in the Healthy Adult Status. *Clin. Chim. Acta* 451, 97–102. doi: 10.1016/j.cca.2015.01.003

Dethlefsen, L., and Relman David, A. (2011). Incomplete Recovery and Individualized Responses of the Human Distal Gut Microbiota to Repeated Antibiotic Perturbation. *Proc. Natl. Acad. Sci.* 108, 4554–4561. doi: 10.1073/pnas.1000807107

Dethlefsen, L., and Relman David, A. (2011). Microbiota, Cirrhosis, and the Emerging Oral-Gut-Liver Axis. *JCI Insight* 2 (19), e94416. doi: 10.1172/jci.insight.94416

Liang, Z. D., Ke, S., and Dupont, H. L. (2010). Rifaximin-Induced Alteration of Virulence of Diarrhoea-Producing Escherichia Coli and Shigella Sonnei. *Int. J. Antimicrob Agents* 35, 278–281. doi: 10.1016/j.ijantimicag.2009.11.013

Kaji, K., Takaya, H., Saikawa, S., Furukawa, M., Sato, S., Kawarathani, et al. (2017). Rifaximin Ameliorates Hepatic Encephalopathy and Endotoxemia Without Affecting the Gut Microbiome Diversity. *World J. Gastroenterol.* 23, 8355–8366. doi: 10.3748/wg.v23.i47.8355

Kogawa, A. C., and Salgado, H. R. N. (2018). Status of Rifaximin: A Review of Characteristics, Uses and Analytical Methods. *Crit. Rev. Anal. Chem.* 48, 459–466. doi: 10.1080/10408347.2018.1447355

Lambeau, G., Andrikova, I., Vornic, M. A., Mielke, S., Hofmann, W. P., et al. (2020). Management of Hepatic Encephalopathy in Germany: A Survey Among Physicians. *Z. fur Gastroenterologie* 58, 49–56. doi: 10.1055/s-0035-1587159.

LePage, P., Lederc, M. C., Joossens, M., Mondot, S., Blottière, H. M., Raes, J., et al. (2013). A Metagenomic Insight Into Our Gut’s Microbiome. *Gut* 62, 146–158. doi: 10.1136/gutjnl-2011-301805

Ley, R. E., Turnbaugh, P. J., Klein, S., and Gordon, J. I. (2006). Microbial Ecology: Human Gut Microbes Associated With Obesity. *Nature* 444, 1022–1023. doi: 10.1038/4441022a

Llorente, C., and Schnabl, B. (2015). The Gut Microbiota and Liver Disease. *Cell. Mol. Gastroenterol. Hepatol.* 1, 275–284. doi: 10.1016/j.cgmh.2015.04.003

**SUPPLEMENTARY MATERIAL**

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fcimb.2021.761192/full#supplementary-material

**ACKNOWLEDGMENTS**

We thank Jinru Ji, Chaoqun Ying, and Hao Xu for their help with sample collection.
Lv, X. Y., Ding, H. G., Zheng, J. F., Fan, C. L., and Li, L. (2020). Rifaximin Improves Survival in Cirrhotic Patients With Refractory Ascites: A Real-World Study. World J. Gastroenterol. 26, 199–218. doi: 10.3748/wjg.v26.i2.199

Metcalfe, S., Baker, M. G., Freeman, J., Wilson, N., and Murray, P. (2016). Combating Antimicrobial Resistance Demands Nation-Wide Action and Global Governance. N Z Med. J. 129, 8–14.

Miquel, S., Martin, R., Rossi, O., Bermúdez-Humarán, L. G., Chatel, J. M., et al. (2013). Faecalibacterium Prausnitzii and Human Intestinal Health. Curr. Opin. Microbiol. 16, 255–261. doi: 10.1016/j.mib.2013.06.003

Morgun, A., Dzutsev, A., Dong, X., Greer, R. L., Sexton, D. J., Ravel, J., et al. (2015). Altered Microbiota in a Patient With Obstructive Chronic Liver Disease Isolated From Feces of a Healthy Japanese Male. Microbiol. Resour Announcements 9 (7), e01543–19. doi: 10.1128/MRA.01543-19

Qin, N., Yang, F., Li, A., Prifti, E., Chen, Y., Shao, L., et al. (2014). Alterations of the Human Gut Microbiome in Liver Cirrhosis. Nature 513, 59–64. doi: 10.1038/ nature13568

Raymond, F., Ouameur, A. A., Deraspe, M., Iqbal, N., Gingras, H., et al. (2016). The Initial State of the Human Gut Microbiome Determines its Reshaping by Antibiotics. ISME J. 10, 707–720. doi: 10.1038/ismej.2015.148

Reijnders, D., Goossens, G. H., Hermes, G. D., Neis, E. P., van der Beek, C. M., Most, J., et al. (2016). Effects of Gut Microbiota Manipulation by Antibiotics on Host Metabolism in Obese Humans: A Randomized Double-Blind Placebo-Controlled Trial. Cell Metab. 24, 63–74. doi: 10.1016/j.cmet.2016.06.016

Ridlon, J. M., Alves, J. M., Hylemon, P. B., and Bajaj, J. S. (2013). Cirrhosis, Bile Acids and Gut Microbiota: Unraveling a Complex Relationship. Gut Microbes 4, 382–387. doi: 10.4161/gmic.25723

Riggo, O., Masini, A., Efreti, C., Nicolao, F., Angeloni, S., Salvatori, F. M., et al. (2005). Pharmacological Prophylaxis of Hepatic Encephalopathy After Transjugular Intrahepatic Portosystemic Shunt: A Randomized Controlled Study. J. Hepatol. 42, 674–679. doi: 10.1016/j.jhep.2004.12.028

Sokol, H., Pigneur, B., Watterlot, L., Lakhdari, O., Bermúdez-Humarán, L. G., et al. (2008). Faecalibacterium Prausnitzii is an Anti-Inflammatory Commensal Bacterium Identified by Gut Microbiota Analysis of Crohn Disease Patients. Proc. Natl. Acad. Sci. 105, 16731–16736. doi: 10.1073/pnas.0804812105

Song, J. J., Tian, W. J., Kwok, L. Y., Wang, Y. L., Shang, Y. N., Menghe, B., et al. (2017). Effects of Microencapsulated Lactobacillus Plantarum LJP-1 on the Gut Microbiota of Hyperlipidemic Rats. Br. J. Nutr. 118, 481–492. doi: 10.1017/ S0007114517002380

Sung, C. M., Lin, Y. F., Chen, K. F., Ke, H. M., Huang, H. Y., Gong, Y. N., et al. (2019). Predicting Clinical Outcomes of Cirrhosis Patients With Hepatic Encephalopathy From the Fecal Microbiome. Cell. Mol. Gastroenterol. Hepatol. 8, 301–318.e2. doi: 10.1016/j.cmg.2019.04.008

Yu, J., Jin, Z., Xiao, W., Wu, S., Gao, X., Shen, Z., Luo, L., and Xiao, Y. (2018). Antimicrobial Stewardship in China: Systems, Actions and Future Strategies. Clin. Infect. Dis. an Off. Publ. Infect. Dis. Soc. Am 67, S135–S541. doi: 10.1093/cid/ciy641

Zhu, L., Lu, X., Liu, L., Vogmeir, J., Zhong, X., and Yu, Q. (2020). Akkermansia Muciniphila Protects Intestinal Mucosa From Damage Caused by S. Pullorum by Initiating Proliferation of Intestinal Epithelium. Vet Res. 51, 34. doi: 10.1186/s13567-020-00735-3

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Yu, J., Jin, Z., Xiao, W., Wu, S., Gao, X., Shen, Z., Luo, L., and Xiao. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.